ABSTRACT
Objectives To investigate risk factors for progression to Alzheimer’s disease and related dementias (ADRD) in African Americans and non-Hispanic Caucasians in a large US cohort.
Design A matched case-control design using electronic health records (EHRs) from 2000 – 2017.
Setting Cerner EHRs database covering more than 600 Cerner client hospitals. Participants: 79,120 patients aged 65 and older (#ADRD=39,560, #non ADRD older adults=39,560) from an initial cohort of 49,826,000 patients.
Measurements We converted ICD9 or ICD10 diagnosis codes into PheWas codes to increase clinical relevance. Then we detected ADRD as having both ADRD diagnosis codes and medications. We considered PheWas codes for Alzheimer’s disease, dementia with cerebral degenerations, senile dementia, and vascular dementia. We considered ADRD medications including acetylcholine and memantine.
Results Using two-step propensity score matching, we built an African American cohort of 4,429 and a 4,570-person matched Caucasian cohort that was similar in terms of onset age, observation length, sex, and known ADRD risks (diabetes, vascular disease, heart disease, head injury, and obesity). Older African Americans had a statistically significant progression from cerebrovascular risk (transient ischemic attack) to ADRD incidence (treatment effect coefficient = 0.0978, p-value <0.000) whereas the matched Caucasians did not (treatment effect coefficient = 0.403, p-value = 0.196).
Conclusion Our extensive causal analysis using a nationwide EHR discovered disease progression pathways to ADRD. The carefully matched cohorts from different racial groups showed different progression, which partly explains the racial disparities in ADRD incidence.
IMPACT STATEMENT We certify that this work is confirmatory of recent novel clinical research. We confirmed that cerebrovascular disease increases the risk of ADRD incidence more in older African Americans than in non-Hispanic Caucasians when diabetes is controlled.1,2 This research adds large-scale and nationwide epidemiological evidence on racial disparities due to cerebrovascular risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
YK was supported in part by UTHealth startup, UT Stars award, and the National Institute of Health (NIH) under award number R01GM124111. XJ is CPRIT Scholar in Cancer Research (RR180012), and he was supported in part by Christopher Sarofim Family Professorship, UT Stars award, UTHealth startup, and the National Institute of Health (NIH) under award number R01GM114612 and U01TR002062. PES is supported by NIH, The Weston Brain Institute, The Kleberg Foundation, donations, and numerous pharmaceutical companies. All sponsors did not play a role in the design, methods, subject recruitments, data collections, analysis, and preparation of paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work is reviewed by IRB at University of Texas Health Science Center at Houston (HSC-SBMI-13-0549)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used deidentified Cerner EHRs that University of Texas Health Science Center at Houston subscribes.
